Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma

被引：0
|
作者：
Lian, Bin [1 ]
Mao, Li Li [1 ]
Cui, Chuan Liang [1 ]
Chi, Zhi Hong [1 ]
Si, Lu [1 ]
Sheng, Xi Nan [1 ]
Li, Si Ming [1 ]
Tang, Bi Xia [1 ]
Guo, Jun [1 ]
机构：
[1] Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8506
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma
    Levesque, N.
    Mitchinson, K.
    Lawrie, D.
    Fedorak, L.
    MacDonald, D.
    Normand, C.
    Pouliot, J. F.
    CURRENT ONCOLOGY, 2008, 15 (01) : 36 - 41
  • [42] Radiation recall dermatitis from high-dose interferon alfa-2b
    Thomas, R
    Stea, B
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 355 - 357
  • [43] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Annette
    Schneider, Lars A.
    Podda, Maurizio
    Goeppner, Daniela
    Schadendorf, Dirk
    Weichenthal, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
  • [44] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
    Salans, Mia
    Courtney, Patrick Travis
    Yip, Anthony
    Murphy, James D.
    CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
  • [45] Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma
    Tarhini, A. A.
    Moschos, S. S.
    Schlesselman, J. J.
    Shope-Spotloe, J.
    Demark, M.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Santinami, Mario
    Testori, Alessandro
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Hauschild, Axel
    Musat, Elena
    Spatz, Alain
    Keilholz, Ulrich
    LANCET, 2008, 372 (9633): : 117 - 126
  • [47] Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse’s perspective
    Krista M. Rubin
    Karen Vona
    Kathleen Madden
    Suzanne McGettigan
    Ilana M. Braun
    Supportive Care in Cancer, 2012, 20 : 1601 - 1611
  • [48] Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective
    Rubin, Krista M.
    Vona, Karen
    Madden, Kathleen
    McGettigan, Suzanne
    Braun, Ilana M.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (08) : 1601 - 1611
  • [49] ADJUVANT THERAPY OF STAGE IIIB MELANOMA WITH INTERFERON ALFA-2B - CLINICAL AND IMMUNOLOGICAL RELEVANCE
    DOVEIL, GC
    FIERRO, MT
    NOVELLI, M
    APPINO, A
    BERTERO, M
    QUAGLINO, P
    BERNENGO, MG
    DERMATOLOGY, 1995, 191 (03) : 234 - 239
  • [50] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, TJ
    Borden, EC
    Blum, RH
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 7 - 17
12345